Article
[Immunohistochemical detections of EGFR mutations in NSCLC].
Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Sept 2014
Liu Chang, Xu Dongbo, Zhong Diansheng
Abstract excerpt
In recent years, it has been well known that non-small cell lung cancer (NSCLC) patients with mutations of epidermal growth factor receptor (EGFR) response better to EGFR-tyrosine kinase inhibitor treatment. Although DNA-based assays (e.g. DNA sequencing) are the most frequently used and a relatively reliable method to detect EGFR mutations, they are complex, time-consuming and relatively expensive for routine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
